Trial Profile
Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary) ; Palbociclib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Mar 2024 Planned End Date changed from 31 Mar 2024 to 30 Jun 2025.
- 15 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 09 Jan 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.